BIOLASE Announces $5 Million Registered Direct Offering

BIOLASE Announces $5 Million Registered Direct Offering 
IRVINE, CA -- (Marketwired) -- 09/24/13 --  BIOLASE, Inc. (NASDAQ:
BIOL), the world's leading manufacturer and distributor of dental
lasers, and a pioneer in laser surgery in other medical specialties,
today announced that it has received a commitment from Camber Capital
Management, LLC ("Camber") to purchase an aggregate of $5 million of
its common stock. 
Camber entered into a definitive subscription agreement with BIOLASE
pursuant to which it subscribed for an aggregate of 2,688,172 shares
of BIOLASE's common stock at $1.86 per share, a price equal to the
closing price on September 23, 2013. The closing of the offering is
expected to take place on or about September 27, 2013, subject to the
satisfaction of customary closing conditions. 
Northland Securities, Inc. acted as exclusive placement agent in
connection with the offering. 
A shelf registration statement (File No. 333-190158) relating to the
shares issued in the offering has been filed with and declared
effective by the Securities and Exchange Commission (the "SEC"). A
prospectus supplement relating to the offering will be filed by
BIOLASE with the SEC. Copies of the prospectus supplement, together
with the accompanying prospectus, can be obtained at the SEC's
website at, at request from Northland Securities,
Inc. by e-mailing Andrew Pafko at,
or from BIOLASE, Inc., 4 Cromwell, Irvine, California 92618. 
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities of BIOLASE in this
offering. There shall not be any offer, solicitation of an offer to
buy, or for the sale of securities in any state or jurisdiction in
which such an offering, solicitation, or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or jurisdiction. Any offering will be made only by means
of a prospectus, including a prospectus supplement, forming a part of
the effective registration statement. 
About BIOLASE, Inc.
 BIOLASE, Inc. is a biomedical company that
develops, manufactures, and markets innovative lasers in dentistry
and medicine and also markets and distributes high-end 2D and 3D
digital imaging equipment and CAD/CAM intraoral scanners; products
that are focused on technologies that advance the practice of
dentistry and medicine. The Company's proprietary laser products
incorporate approximately 315 patented and patent-pending
technologies designed to provide biologically clinically superior
performance with less pain and faster recovery times. Its innovative
products provide cutting-edge technology at competitive prices to
deliver the best results for dentists and patients. BIOLASE's
principal products are revolutionary dental laser systems that
perform a broad range of dental procedures, including cosmetic and
complex surgical applications, and a full line of dental imaging
equipment. BIOLASE has sold more than 23,000 lasers. Other laser
products under development address ophthalmology and other medical
and consumer markets. 
For updates and information on WaterLase(R) and laser dentistry, find
BIOLASE online at, Facebook at, Twitter at,
Pinterest at, LinkedIn at, Instagram at and YouTube at 
BIOLASE(R) and WaterLase(R) are registered trademarks of BIOLASE,
Additional Information
 Statements made in this press release include
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, regarding, but not limited to, the
amount BIOLASE expects to receive from the offering and the timing
for the closing of the offering. Forward-looking statements can be
identified by the use of words such as "may," "will," "plan,"
"should," "expect," "anticipate," "estimate," "continue," or
comparable terminology. Such forward-looking statements are
inherently subject to certain risks, trends and uncertainties, many
of which BIOLASE cannot predict with accuracy and some of which
BIOLASE might not even anticipate, and involve factors that may cause
actual results to differ materially from those projected or
suggested. These risks and uncertainties include, among others, the
factors described under the Risk Factors section of BIOLASE's Annual
Reports on Form 10-K and Quarterly Reports on Form 10-Q filed with
the SEC. BIOLASE cautions investors not to place considerable
reliance on the forward-looking statements contained in this release.
These statements speak only as of the date of this press release, and
BIOLASE undertakes no obligation to update or revise the statements.  
For further information, please contact: 
Michael Porter 
Porter, LeVay & Rose, Inc. 
Press spacebar to pause and continue. Press esc to stop.